WO2023106645A1 - Composition for preventing or treating muscular diseases containing ginsenoside rg5 - Google Patents
Composition for preventing or treating muscular diseases containing ginsenoside rg5 Download PDFInfo
- Publication number
- WO2023106645A1 WO2023106645A1 PCT/KR2022/017181 KR2022017181W WO2023106645A1 WO 2023106645 A1 WO2023106645 A1 WO 2023106645A1 KR 2022017181 W KR2022017181 W KR 2022017181W WO 2023106645 A1 WO2023106645 A1 WO 2023106645A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- muscle
- composition
- ginsenoside
- present
- active ingredient
- Prior art date
Links
- NJUXRKMKOFXMRX-RNCAKNGISA-N Ginsenoside Rg5 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NJUXRKMKOFXMRX-RNCAKNGISA-N 0.000 title claims abstract description 65
- NJUXRKMKOFXMRX-AXUZFSSLSA-N ginsenoside Rg5 Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@@H]4CC[C@@]23C)C NJUXRKMKOFXMRX-AXUZFSSLSA-N 0.000 title claims abstract description 65
- NJUXRKMKOFXMRX-UHFFFAOYSA-N ginsenoside Rz1 Natural products CC(C)=CCC=C(C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 208000021642 Muscular disease Diseases 0.000 title abstract description 5
- 210000003205 muscle Anatomy 0.000 claims abstract description 48
- 230000004069 differentiation Effects 0.000 claims abstract description 36
- 210000003098 myoblast Anatomy 0.000 claims abstract description 20
- 238000005728 strengthening Methods 0.000 claims abstract description 10
- 230000009756 muscle regeneration Effects 0.000 claims abstract description 9
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims description 32
- 208000029578 Muscle disease Diseases 0.000 claims description 28
- 235000013376 functional food Nutrition 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 208000001076 sarcopenia Diseases 0.000 claims description 12
- 230000001737 promoting effect Effects 0.000 claims description 11
- 239000003674 animal food additive Substances 0.000 claims description 7
- 201000000585 muscular atrophy Diseases 0.000 claims description 7
- 206010028289 Muscle atrophy Diseases 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 206010006895 Cachexia Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 230000036473 myasthenia Effects 0.000 claims description 3
- 208000002740 Muscle Rigidity Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 230000003387 muscular Effects 0.000 abstract 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 13
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000032683 aging Effects 0.000 description 10
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 9
- 229960003957 dexamethasone Drugs 0.000 description 9
- 210000000663 muscle cell Anatomy 0.000 description 9
- 241000208340 Araliaceae Species 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 description 8
- 235000008434 ginseng Nutrition 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 210000004262 dental pulp cavity Anatomy 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000107 myocyte Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 3
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 3
- 102100040669 F-box only protein 32 Human genes 0.000 description 3
- 101710191029 F-box only protein 32 Proteins 0.000 description 3
- 102000004364 Myogenin Human genes 0.000 description 3
- 108010056785 Myogenin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102000004987 Troponin T Human genes 0.000 description 3
- 108090001108 Troponin T Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000001114 myogenic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- -1 aromatics Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001189 slow twitch fiber Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZMJOVJSTYLQINE-UHFFFAOYSA-N Dichloroacetylene Chemical compound ClC#CCl ZMJOVJSTYLQINE-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003854 type 2 muscle cell Anatomy 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
Definitions
- the present invention relates to the prevention and treatment of muscle diseases, particularly sarcopenia, and relates to a composition for preventing, improving or treating muscle diseases comprising Rg5 isolated from extracts of red ginseng and black ginseng as an active ingredient.
- Muscles account for an important part of body functions such as energy metabolism and exercise capacity, and can be damaged or weakened by various factors such as sarcopenia caused by aging, muscular atrophy due to nutritional imbalance or lack of exercise, other diseases such as cancer, and aging. there is.
- Sarcopenia a major disease that damages muscles, is a disease in which muscle strength decreases as skletal muscle mass decreases with aging.
- the most significant feature of sarcopenia is a decrease in muscle mass, and the type of muscle fiber may change. While type 1 muscle fibers and type 2 muscle fibers decrease at a similar rate with aging, type 1 muscle fiber thickness decreases more noticeably in patients with sarcopenia. It has been reported that such sarcopenia causes muscle weakness and functional impairment among the elderly (Roubenoff R., Can. J. Appl. Physiol. 26, 78-89, 2001). As such, the decrease in skeletal muscle mass and strength as a result of aging not only reduces muscle function but also increases the risk of developing chronic metabolic diseases.
- Sarcopenia can be caused by aging, but can also be caused by diseases such as diabetes, cancer, and spinal stenosis.
- Black ginseng is made by steaming and processing ginseng using the Gujeunggupo method, which is known to contain various ginsenoside components. Results have been reported that black ginseng has an effect on metabolic diseases such as diabetes, and nothing is known about its muscle-related effects.
- the present inventors found that among various ginsenoside components extracted from black ginseng, Rg5 in particular promotes differentiation of myoblasts to increase muscle mass and improve muscle strength, and in particular, to have therapeutic effects on muscle diseases such as muscular dystrophy. , completed the present invention.
- an object of the present invention is to provide a composition for myoblast differentiation comprising ginsenoside Rg5 as an active ingredient.
- Another object of the present invention is to provide a composition for promoting muscle regeneration comprising ginsenoside Rg5 as an active ingredient.
- Another object of the present invention is to provide a composition for increasing muscle mass containing ginsenoside Rg5 as an active ingredient.
- Another object of the present invention is to provide a composition for strengthening muscle strength or improving exercise performance containing ginsenoside Rg5 as an active ingredient.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- Another object of the present invention is to provide a health functional food, functional food, or food supplement for preventing or improving muscle diseases containing ginsenoside Rg5 as an active ingredient.
- Another object of the present invention is to provide a feed or feed additive composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- the present invention provides a composition for myoblast differentiation comprising ginsenoside Rg5 as an active ingredient.
- the present invention provides a composition for promoting muscle regeneration comprising ginsenoside Rg5 as an active ingredient.
- the present invention provides a composition for increasing muscle mass containing ginsenoside Rg5 as an active ingredient.
- the present invention provides a composition for strengthening muscle strength or improving exercise performance containing ginsenoside Rg5 as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- the present invention provides a health functional food, functional food, or food additive for preventing or improving muscle disease, containing ginsenoside Rg5 as an active ingredient.
- the present invention provides a feed or feed additive composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- the present invention relates to a composition containing ginsenoside Rg5 as an active ingredient, which has an effect of promoting myocyte differentiation, muscle regeneration, muscle mass increase or muscle strength improvement.
- Ginsenoside Rg5 corresponds to a low molecular weight ginsenoside among ginsenosides isolated from ginseng, and is known to have effects such as improving memory, anti-inflammatory, and antioxidant.
- Ginsenoside Rg5 can be extracted from ginseng, red ginseng or black ginseng, but is not limited thereto, and in the extraction method, in the group consisting of hot water extraction, reflux extraction, hot water extraction, cold needle extraction, room temperature extraction, ultrasonic extraction or steam extraction Any one or more selected extraction methods may be used, and the method is not particularly limited.
- ginsenoside Rg5 has a myogenic cell differentiation promoting effect.
- the "differentiation of myoblasts” means a process in which mononuclear myoblasts form multinucleated myotubes through fusion, and cells in the differentiation stage that form myotubes are Pax7-, MyoD+, MyoG, etc. They can be distinguished using markers.
- the expression of myogenic transcription factors such as myosin D (Myo D) is increased in the cells at the early stage of differentiation forming the myotubes, and in the middle stage, myosin G (MyoG) is increased.
- Myosin Heavy Chain MHC
- Fig. 2 Myosin Heavy Chain
- the ginsenoside Rg5 of the present invention has an effect of promoting muscle cell regeneration.
- muscle regeneration refers to the ability of damaged muscles to recover to normal.
- the muscle regeneration may be an effect of an increase in the absolute amount of muscle cells by promoting differentiation of muscle cells or an increase in the diameter of individual root canals.
- the above effects may be present in not only normal muscles but also damaged muscles or muscles with muscular dystrophy, and thus may have an effect of preventing, improving, or treating symptoms of muscle diseases such as muscular dystrophy.
- ginsenoside Rg5 of the present invention has a muscle strength improving effect.
- Muscle mass can be increased through the above-mentioned root canal formation and myoblast differentiation promotion effects, thereby improving muscle strength and further improving exercise performance.
- Increase in muscle mass means an increase in the amount of muscle compared to other parts of body tissue, and an increase in the amount of muscle relative to body weight.
- “Strengthening muscle strength” means enhancement of physical performance, enhancement of maximum endurance, increase of muscle mass, enhancement of muscle recovery, increase of oxidative muscle mass, reduction of muscle fatigue, improvement of energy balance, or a combination thereof.
- Ginsenoside Rg5 of the present invention may have an effect of increasing muscle mass through differentiation of myoblasts, strengthening muscle strength, and enhancing exercise performance through muscle.
- composition for promoting myoblast differentiation, for increasing muscle mass, and for strengthening muscle strength of the present invention may be prepared in the form of a pharmaceutical composition, health functional food, functional food or food additive (supplement). That is, the composition for strengthening muscle strength of the present invention can be used in the form of an adjuvant for muscle generation and muscle strengthening in the general public as well as muscle loss due to aging.
- the present invention relates to a composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- the "muscle disease” refers to a state in which muscle strength is weakened due to muscle damage or loss due to aging or disease, which is due to genetic predisposition, hypertension, impaired glucose tolerance, diabetes, obesity, dyslipidemia, atherosclerosis or cardiovascular disease.
- age-related diseases such as diseases; Diseases such as cancer, autoimmune diseases, infectious diseases, AIDS, chronic inflammatory diseases, arthritis, malnutrition, kidney disease, chronic obstructive pulmonary disease, emphysema, rickets, chronic lower back pain, peripheral nerve damage, central nerve damage and chemical damage chronic diseases such as; loss of motion due to causes such as fractures, trauma, etc., or prolonged bed rest; It can be caused by various causes such as aging.
- the muscle diseases include atony, muscular atrophy, muscular dystrophy, muscle degeneration, muscle stiffness, amyotrophic sclerosis, myasthenia, cachexia and geriatric sarcopenia.
- sarcopenia may be one or more muscle diseases selected from the group consisting of.
- the muscle disease may be at least one muscle disease selected from the group consisting of muscular atrophy, sarcopenia due to aging, or muscular dystrophy.
- prevention refers to all actions capable of suppressing or delaying the onset of muscle diseases by administration of the pharmaceutical composition according to the present invention.
- treatment refers to all activities that improve or benefit symptoms by administration of the pharmaceutical composition according to the present invention.
- the pharmaceutical composition of the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods. and may further include carriers or excipients necessary for the formulation.
- Pharmaceutically acceptable carriers, excipients and diluents that may be further included in the active ingredient include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oil; and the like. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient at least cotton, starch, calcium carbonate, etc. in the extract or compound. It is prepared by mixing sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
- injectable esters such as ethyl oleate
- witepsol, macrogol, tween 61, cacao butter, laurin fat, glycerogeratin and the like may be used as a base for the suppository.
- the pharmaceutical composition of the present invention may be administered orally or parenterally (intravenously, subcutaneously, intraperitoneally or topically applied) depending on the desired method, and the dosage may be the condition and weight of the patient, the severity of the disease and the type of drug, Depending on the route and time of administration, it can be selected in an appropriate form by those skilled in the art.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means a reasonable amount applicable to medical treatment, an amount sufficient to treat a disease, and the standard is the patient's disease, severity, drug activity, sensitivity to the drug, administration time , route of administration and excretion rate, duration of treatment, concomitant components, and other factors.
- the pharmaceutical composition of the present invention may be administered individually or in combination with other therapeutic agents, or may be administered sequentially or simultaneously with conventional therapeutic agents. The dosage can be determined at a level that can minimize side effects by considering all of the above factors, which can be easily determined by a person skilled in the art.
- the dosage of the pharmaceutical composition may vary depending on the patient's age, weight, severity, sex, etc., and is generally 0.001 to 150 mg per 1 kg of body weight, more preferably 0.01 to 100 mg per day or every other day, 1 It can be administered 1 to 3 times a day. However, this is exemplary, and the dosage may be set differently if necessary.
- composition of the present invention may be a functional food, food supplement or health functional food, and in particular, the "health functional food” uses raw materials or components having useful functionality for the human body according to Health Functional Food Act No. 6727.
- “Functional” refers to food that has been manufactured and processed, and “functional” means to be ingested for the purpose of obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological actions.
- the food or health functional food of the present invention for the purpose of preventing and improving muscle diseases, is a pharmaceutical dosage form such as powder, granule, tablet, capsule, pill, suspension, emulsion, syrup, or tea bag, leachate, beverage, It can be manufactured and processed into health functional foods such as candy, jelly, and gum.
- the food or health functional food composition of the present invention can be used as a food additive, and can be commercialized alone or in combination with other ingredients.
- nutrients, vitamins, electrolytes, flavoring agents, colorants and enhancers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, used in carbonated beverages A carbonation agent and the like may be included.
- the above components may be used alone or in combination, and may be used in combination in an appropriate amount.
- the present invention relates to a feed or feed additive composition containing ginsenoside Rg5.
- 'feed' means a material that supplies organic or inorganic nutrients necessary for maintaining the life of an animal.
- the feed includes nutrients such as energy, protein, lipid, vitamins, and minerals required by animals such as livestock, and includes grains, roots and fruits, food processing by-products, algae, fibers, oils, starches, It may be vegetable feed such as grain by-products or animal feed such as proteins, inorganic materials, oils, minerals, oils, and single cell proteins, but is not limited thereto.
- 'feed additive' means a substance added to feed to improve productivity or health of animals, but is not limited thereto, but is not limited thereto, such as amino acids, vitamins, enzymes, A flavoring agent, a silicate agent, a buffering agent, an extracting agent, an oligosaccharide, and the like may be further included.
- the content of ginsenoside Rg5 contained in the feed or feed additive of the present invention is not particularly limited thereto, but may be 0.001 to 1% (w/w), preferably 0.005 to 0.9% (w/w). It may be, and most preferably may be 0.01 to 0.5% (w / w).
- the present invention is a composition containing ginsenoside Rg5, which promotes differentiation of myoblasts, increases muscle mass, improves muscle strength and/or increases exercise performance, and may have preventive, ameliorative, or therapeutic effects on muscle diseases. .
- Figure 2 is a Western blot showing the expression of myoblast differentiation markers in C2C12 cells treated with ginsenoside Rg5 at different concentrations.
- 3 and 4 show the results confirming the increase in MHC-expressing cells in muscle cells 3 days after C2C12 was treated with ginsenoside Rg5.
- 5a and 5b show the results of confirming the diameter and recovery of myotube cells in the case of treatment with ginsenoside Rg5 after inducing muscle damage by treatment with dexamethasone.
- Figure 6 confirms the effect of ginsenoside Rg5 on the recovery of protein degradation in muscle cells upon treatment with dexamethasone.
- the expression of Atrogin-1 increased, but when treated with ginsenoside Rg5, it was confirmed that the expression was reduced (Fig. 6a), and also, it was confirmed that the mRNA expression level of MuRF1 was reduced (Fig. 6b) .
- C2Cl2 is a myogenic cell line obtained from live mice of the C3H species, and is widely used in myocyte differentiation studies.
- the C2C12 cells were cultured in a general cell culture medium and a differentiation medium, respectively.
- DMEM supplemented with 10% fetal bovine serum was used as normal growth media (GM), and DMEM containing 2% horse serum was used as differentiation media (DM). did
- Ginsenoside Rg5 was purchased and used as a commercially available raw material (Ambo Institute).
- ginsenoside Rg5 (0(DMSO), 30, 100, 300 and 1000 n ⁇ ) was added to the differentiation medium by concentration, respectively. treatment and differentiation was induced for 3 days while the medium was replaced every other day.
- the cells were observed under a microscope, and the cells were disrupted and Western blot analysis was performed using the differentiation markers MHC (myosin heavy chain), Troponin-T, and Myogenin antibodies. In addition, an MTT assay was performed to determine whether ginsenoside Rg5 was cytotoxic.
- MHC myosin heavy chain
- Troponin-T Troponin-T
- Myogenin antibodies Myogenin antibodies
- ginsenoside Rg5 After adding differentiation induction medium containing 300 nM of ginsenoside Rg5 to the culture medium, muscle cells (multinucleated) were cultured for 3 days. Thereafter, in order to confirm MHC expression in muscle cells, it was confirmed through fluorescence staining together with the untreated group. As a result, as shown in FIGS. 3 and 4, it was confirmed that the number of cells expressing MHC increased after 48 hours of treatment with ginsenoside Rg5. From the above results, it can be confirmed that ginsenoside Rg5 has an effect of promoting the differentiation of myoblasts into muscle cells.
- ginsenoside Rg5 exhibits a therapeutic effect on actual muscle diseases.
- DEX dexamethasone
- an experiment using C2C12 myoblasts was performed. After differentiation of C2C12 myoblasts was induced in differentiation medium (DM) for 3 days, they were pretreated with 100 mM dexamethasone (DEX) for 4 hours. Thereafter, ginsenoside Rg5 and DMSO were treated with 300 nM, respectively, and cultured in a differentiation medium for 24 hours. Thereafter, immunocytochemical staining was performed using an MHC antibody and analyzed by fluorescence microscopy.
- Atrogin-1 and MuRF1 which can confirm muscular dystrophy.
- FIG. 6 As a result of comparative analysis of western blot and mRNA expression levels of the markers, it was confirmed that Atrogin-1 protein expression was reduced and MuRF1 mRNA expression was significantly reduced compared to the control group when ginsenoside Rg5 was treated.
- the present invention relates to a composition for myoblast differentiation comprising ginsenoside Rg5 as an active ingredient.
- the present invention relates to a composition for promoting muscle regeneration comprising ginsenoside Rg5 as an active ingredient.
- the present invention relates to a composition for increasing muscle mass comprising ginsenoside Rg5 as an active ingredient.
- the present invention relates to a composition for strengthening muscle strength or improving exercise performance containing ginsenoside Rg5 as an active ingredient.
- the composition may be one or more selected from a pharmaceutical composition, a health functional food composition, a food additive composition, or a feed composition.
- the present invention relates to a pharmaceutical composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- the present invention relates to a health functional food composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- the present invention relates to a feed or feed additive composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- the muscular disease includes atony, muscular atrophy, muscular dystrophy, muscle degeneration, muscle stiffness, amyotrophic sclerosis, myasthenia, cachexia and sarcopenia. It may be selected from the group containing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition for preventing, alleviating, or treating muscular diseases containing ginsenoside Rg5. The composition promotes the differentiation of myoblasts to increase muscle mass, has a muscle regeneration effect in muscles damaged by muscular diseases such as muscular dystrophy, improves exercise performance by strengthening muscular strength, and has an effect of preventing, alleviating, and treating various muscular diseases.
Description
본 발명은 근육 질환, 특히 근감소증의 예방 및 치료에 관한 것으로, 홍삼 및 흑삼의 추출물에서 분리된 Rg5를 유효성분으로 포함하는 근육질환 예방, 개선 또는 치료용 조성물에 대한 것이다. The present invention relates to the prevention and treatment of muscle diseases, particularly sarcopenia, and relates to a composition for preventing, improving or treating muscle diseases comprising Rg5 isolated from extracts of red ginseng and black ginseng as an active ingredient.
근육은 에너지 대사, 운동 능력 등 신체 기능의 중요한 부분을 차지하며, 노화에 의한 근감소증, 영양 불균형 또는 운동량 부족에 의한 근위축증, 기타 암과 같은 다른 질환, 노화 등 다양한 요인에 의해 손상되거나 약화될 수 있다. Muscles account for an important part of body functions such as energy metabolism and exercise capacity, and can be damaged or weakened by various factors such as sarcopenia caused by aging, muscular atrophy due to nutritional imbalance or lack of exercise, other diseases such as cancer, and aging. there is.
근육을 손상시키는 주요 질환인 근감소증(sarcopenia)은 노화에 의하여 근육량(skletal muscle mass)이 감소됨에 따라 근력이 저하되는 질환이다. 근감소증의 가장 큰 특징은 근육량의 감소이며, 근섬유의 종류가 변화하기도 한다. 노화에 따라 타입 1 근섬유 및 타입 2 근섬유가 비슷한 비율로 감소하는데 반해, 근감소증 환자에서 타입 1 근섬유 두께가 더욱 눈에 띄게 감소한다. 이러한 근감소증은 노인들 사이에서 일어나는 근력 저하와 기능 장애를 유발한다고 보고되고 있다(Roubenoff R., Can. J. Appl. Physiol. 26, 78-89, 2001). 이렇듯 노화의 결과로 골격근량과 근력이 감소하면 이로 인해 근육 기능이 감소될 뿐만 아니라 만성적 대사 질환의 발병 위험이 높아진다. 근 감소증은 노화가 원인이 되기도 하지만 당뇨병, 암, 척추 협착증과 같은 질환에 의하여 발생되기도 한다. Sarcopenia, a major disease that damages muscles, is a disease in which muscle strength decreases as skletal muscle mass decreases with aging. The most significant feature of sarcopenia is a decrease in muscle mass, and the type of muscle fiber may change. While type 1 muscle fibers and type 2 muscle fibers decrease at a similar rate with aging, type 1 muscle fiber thickness decreases more noticeably in patients with sarcopenia. It has been reported that such sarcopenia causes muscle weakness and functional impairment among the elderly (Roubenoff R., Can. J. Appl. Physiol. 26, 78-89, 2001). As such, the decrease in skeletal muscle mass and strength as a result of aging not only reduces muscle function but also increases the risk of developing chronic metabolic diseases. Sarcopenia can be caused by aging, but can also be caused by diseases such as diabetes, cancer, and spinal stenosis.
이러한 근육 질환을 근본적으로 치료하기 위한 다양한 치료 방법이 개발중에 있으며, 줄기세포치료법, 근육 분화 촉진 등이 이에 포함된다. 또한, 이러한 치료법 이외에 보다 접근이 용이하며 부작용이 없는 천연 물질을 이용하여 증상을 개선하거나, 치료할 수 있는 치료 물질에 대한 연구도 함께 진행되고 있는 실정이다. Various treatment methods for fundamentally treating these muscle diseases are being developed, and include stem cell therapy, muscle differentiation promotion, and the like. In addition to these therapies, studies on therapeutic substances that can improve or treat symptoms using natural substances that are more accessible and have no side effects are also being conducted.
흑삼은 구증구포(九蒸九曝) 방식으로 삼을 쪄서 가공하는 방식으로 만들어지는 것으로, 여기에는 다양한 진세노사이드(ginsenoside) 성분이 함유되어 있는 것으로 알려져 있다. 흑삼은 당뇨병과 같은 대사성 질환에 효과를 가진다는 결과가 보고되어 있으며, 아직까지 근육과 관련된 효과에 대해서는 알려진 바가 없다.Black ginseng is made by steaming and processing ginseng using the Gujeunggupo method, which is known to contain various ginsenoside components. Results have been reported that black ginseng has an effect on metabolic diseases such as diabetes, and nothing is known about its muscle-related effects.
본 발명자들은 흑삼으로부터 추출되는 다양한 진세노사이드 성분들 중, 특히 Rg5가 근원세포 분화를 촉진하여 근육량을 증가시키고, 근력을 향상시킬 수 있으며, 특히 근위축증과 같은 근육 질환에도 치료 효과가 있음을 발견하고, 본 발명을 완성하였다. The present inventors found that among various ginsenoside components extracted from black ginseng, Rg5 in particular promotes differentiation of myoblasts to increase muscle mass and improve muscle strength, and in particular, to have therapeutic effects on muscle diseases such as muscular dystrophy. , completed the present invention.
따라서 본 발명의 목적은 진세노사이드 Rg5을 유효 성분으로 포함하는 근원세포 분화용 조성물을 제공하는 것이다. Accordingly, an object of the present invention is to provide a composition for myoblast differentiation comprising ginsenoside Rg5 as an active ingredient.
본 발명의 다른 목적은 진세노사이드 Rg5를 유효 성분으로 포함하는 근육 재생 촉진용 조성물을 제공하는 것이다. Another object of the present invention is to provide a composition for promoting muscle regeneration comprising ginsenoside Rg5 as an active ingredient.
본 발명의 다른 목적은 진세노사이드 Rg5을 유효 성분으로 포함하는 근육량 증가용 조성물을 제공하는 것이다. Another object of the present invention is to provide a composition for increasing muscle mass containing ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 목적은 진세노사이드 Rg5를 유효 성분으로 포함하는 근력 강화 또는 운동 수행능력 향상용 조성물을 제공하는 것이다. Another object of the present invention is to provide a composition for strengthening muscle strength or improving exercise performance containing ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 목적은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다. Another object of the present invention is to provide a pharmaceutical composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 목적은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 개선용 건강 기능식품, 기능성 식품 또는 식품 보조제를 제공하는 것이다. Another object of the present invention is to provide a health functional food, functional food, or food supplement for preventing or improving muscle diseases containing ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 목적은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 개선용 사료 또는 사료 첨가제 조성물을 제공하는 것이다.Another object of the present invention is to provide a feed or feed additive composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
상기와 같은 목적을 달성하기 위하여, 본 발명은 진세노사이드 Rg5을 유효 성분으로 포함하는 근원세포 분화용 조성물을 제공한다. In order to achieve the above object, the present invention provides a composition for myoblast differentiation comprising ginsenoside Rg5 as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 진세노사이드 Rg5를 유효 성분으로 포함하는 근육 재생 촉진용 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a composition for promoting muscle regeneration comprising ginsenoside Rg5 as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 진세노사이드 Rg5을 유효 성분으로 포함하는 근육량 증가용 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a composition for increasing muscle mass containing ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 목적을 달성하기 위하여 본 발명은 진세노사이드 Rg5를 유효 성분으로 포함하는 근력 강화 또는 운동 수행능력 향상용 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a composition for strengthening muscle strength or improving exercise performance containing ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 목적을 달성하기 위하여 본 발명은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 치료용 약학적 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a pharmaceutical composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 목적을 달성하기 위하여 본 발명은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 개선용 건강 기능식품, 기능성 식품 또는 식품 첨가제를 제공한다. In order to achieve another object of the present invention, the present invention provides a health functional food, functional food, or food additive for preventing or improving muscle disease, containing ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 목적을 달성하기 위하여 본 발명은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 개선용 사료 또는 사료 첨가제 조성물을 제공한다.In order to achieve another object of the present invention, the present invention provides a feed or feed additive composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 일 양태로서, 본 발명은 진세노사이드 Rg5를 유효 성분으로 포함하는 조성물로서, 근원세포 분화 촉진, 근육 재생, 근육량 증가 또는 근력 향상 효과를 가지는 조성물에 대한 것이다. As one aspect of the present invention, the present invention relates to a composition containing ginsenoside Rg5 as an active ingredient, which has an effect of promoting myocyte differentiation, muscle regeneration, muscle mass increase or muscle strength improvement.
진세노사이드 Rg5는 인삼으로부터 분리되는 진세노사이드 중에서도 분자량이 적은 저분자 진세노사이드에 해당하며, 기억력 향상, 항염증, 항산화 등의 효능을 가지는 것으로 알려져 있었다. 진세노사이드 Rg5는 인삼, 홍삼 또는 흑삼으로부터 추출될 수 있으며, 이에 제한되는 것은 아니며, 추출 방법에 있어서도 열탕 추출, 환류 추출, 열수 추출, 냉침 추출, 상온 추출, 초음파 추출 또는 증기 추출로 이루어진 군에서 선택되는 어느 하나 이상의 추출 방법을 사용할 수 있으며, 방법에 특별히 제한되는 것은 아니다. Ginsenoside Rg5 corresponds to a low molecular weight ginsenoside among ginsenosides isolated from ginseng, and is known to have effects such as improving memory, anti-inflammatory, and antioxidant. Ginsenoside Rg5 can be extracted from ginseng, red ginseng or black ginseng, but is not limited thereto, and in the extraction method, in the group consisting of hot water extraction, reflux extraction, hot water extraction, cold needle extraction, room temperature extraction, ultrasonic extraction or steam extraction Any one or more selected extraction methods may be used, and the method is not particularly limited.
본 발명에서 진세노사이드 Rg5는 근원세포 분화 촉진 효과를 가진다. 상기 "근원세포 분화" 란, 단핵인 근원세포(myoblast)가 융합을 통해 다핵의 근관(myotube)를 형성하는 과정을 의미하며, 근관을 형성하는 분화단계의 세포는 Pax7-, MyoD+, MyoG 등의 마커를 이용하여 구분할 수 있다. 상기 근관을 형성하는 분화 초기단계의 세포는 마이오신 D(Myo D)와 같은 근원성 전사인자(myogenic transcription factor)의 발현이 증가하며, 중기에는 마이오신 G(MyoG) 가 증가한다. 분화가 거의 끝나는 후기에는 마이오신 중쇄(MHC, Myosin Heavy Chain)의 발현이 증가한다. 본 발명의 일 실시예에서 상기 진세노사이드 Rg5를 근원세포에 처리한 경우, MHC, Myogenin, Troponin-T의 발현이 증가되었음을 확인하였다. (도 2)In the present invention, ginsenoside Rg5 has a myogenic cell differentiation promoting effect. The "differentiation of myoblasts" means a process in which mononuclear myoblasts form multinucleated myotubes through fusion, and cells in the differentiation stage that form myotubes are Pax7-, MyoD+, MyoG, etc. They can be distinguished using markers. The expression of myogenic transcription factors such as myosin D (Myo D) is increased in the cells at the early stage of differentiation forming the myotubes, and in the middle stage, myosin G (MyoG) is increased. In the late stage of differentiation, the expression of Myosin Heavy Chain (MHC) increases. In one embodiment of the present invention, when the myoblasts were treated with the ginsenoside Rg5, it was confirmed that the expression of MHC, Myogenin, and Troponin-T was increased. (Fig. 2)
본 발명의 진세노사이드 Rg5는 근육 세포의 재생을 항진하는 효과를 가진다. 상기 "근육 재생"이란, 손상된 근육이 정상으로 회복될 수 있는 능력을 의미한다. 상기 근육 재생은 근육 세포의 분화가 촉진되어 절대적인 근육 세포의 양이 증가된 것이거나 또는 개개의 근관의 직경이 증가된 것에 의한 효과일 수 있다. 특히 상기 효과는 정상 근육 뿐만 아니라 손상된 근육이나 근 위축증이 유발된 근육에서도 나타날 수 있으며 이로 인하여 근 위축증과 같은 근육 질환의 증상을 예방, 개선 또는 치료할 수 있는 효과를 가질 수 있다. 이와 관련된 본 발명의 일 실시예로부터 확인한 바, 근원세포에 본 발명의 진세노사이드 Rg5를 처리한 경우, 근육세포의 분화가 증가되어 다핵인 MHC+ 근육세포의 발현이 증가된 것을 확인하였다. (도 5, 6)The ginsenoside Rg5 of the present invention has an effect of promoting muscle cell regeneration. The term "muscle regeneration" refers to the ability of damaged muscles to recover to normal. The muscle regeneration may be an effect of an increase in the absolute amount of muscle cells by promoting differentiation of muscle cells or an increase in the diameter of individual root canals. In particular, the above effects may be present in not only normal muscles but also damaged muscles or muscles with muscular dystrophy, and thus may have an effect of preventing, improving, or treating symptoms of muscle diseases such as muscular dystrophy. As confirmed from one example of the present invention related to this, when myoblasts were treated with the ginsenoside Rg5 of the present invention, it was confirmed that the differentiation of myocytes was increased and the expression of multinucleated MHC+ myocytes was increased. (Fig. 5, 6)
또한, 본 발명의 진세노사이드 Rg5는 근력 향상 효과를 가진다. 상기와 같은 근관 형성 및 근원세포 분화 촉진 효과를 통해 근육량이 증가될 수 있으며, 이로 인하여 근력이 향상되며, 나아가 운동 수행능력을 향상시킬 수 있다. "근육량 증가"란, 신체 조직 중 다른 부분에 비하여 근육의 양이 증가되는 것으로, 체중 대비 근육의 양이 증가되는 것을 의미한다. "근력 강화"란, 신체 수행의 강화, 최대 지구력의 강화, 근육량의 증가, 근육 회복의 강화, 산화성 근육량의 증가, 근육피로의 감소, 에너지 수지의 개선 또는 이들의 조합 효과를 의미한다. 본 발명의 진세노사이드 Rg5는 근원세포 분화를 통한 근육량 증가, 근력 강화 및 근육을 통한 운동수행 능력을 증진시키는 효과를 가질 수 있다. In addition, ginsenoside Rg5 of the present invention has a muscle strength improving effect. Muscle mass can be increased through the above-mentioned root canal formation and myoblast differentiation promotion effects, thereby improving muscle strength and further improving exercise performance. "Increase in muscle mass" means an increase in the amount of muscle compared to other parts of body tissue, and an increase in the amount of muscle relative to body weight. "Strengthening muscle strength" means enhancement of physical performance, enhancement of maximum endurance, increase of muscle mass, enhancement of muscle recovery, increase of oxidative muscle mass, reduction of muscle fatigue, improvement of energy balance, or a combination thereof. Ginsenoside Rg5 of the present invention may have an effect of increasing muscle mass through differentiation of myoblasts, strengthening muscle strength, and enhancing exercise performance through muscle.
본 발명의 상기 근원세포 분화 촉진용, 근육량 증가용, 근력 강화용 조성물은 약학적 조성물, 건강기능식품, 기능성 식품 또는 식품 첨가제(보조제) 형태로 제조될 수 있다. 즉, 본 발명의 근력 강화용 조성물은 노화에 의한 근육 감소 뿐만 아니라 일반인의 근육 생성, 근력 강화에 대한 보조제 등의 형태로 이용될 수 있다.The composition for promoting myoblast differentiation, for increasing muscle mass, and for strengthening muscle strength of the present invention may be prepared in the form of a pharmaceutical composition, health functional food, functional food or food additive (supplement). That is, the composition for strengthening muscle strength of the present invention can be used in the form of an adjuvant for muscle generation and muscle strengthening in the general public as well as muscle loss due to aging.
또한, 본 발명의 다른 양태로서, 본 발명은 진세노사이드 Rg5를 유효 성분으로 포함하는 근육 질환의 예방 또는 치료용 조성물에 대한 것이다. 상기 “근육 질환”은 근육이 노화 혹은 질병에 의해 손상되거나 손실되어 근력이 약화된 상태에 있는 것을 의미하며, 이는 유전적 소인, 고혈압, 내당능장애, 당뇨, 비만, 이상지질혈증, 아테롬성경화증 또는 심혈관질환 등의 연령과 관련된 질환; 암, 자가면역질환, 감염성 질환, AIDS, 만성 염증성 질환, 관절염, 영양 실조, 신장 질환, 만성 폐쇄성 폐질환, 폐기종, 구루병, 만성 하부 척추통증, 말초 신경 손상, 중추 신경 손상 및 화학적 손상과 같은 질환 등의 만성 질환; 골절, 외상 등과 같은 원인 혹은 장기간의 침상 요양에 의한 운동 손실; 노화 등 다양한 원인에 의해 기인한 것일 수 있다. In addition, as another aspect of the present invention, the present invention relates to a composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient. The "muscle disease" refers to a state in which muscle strength is weakened due to muscle damage or loss due to aging or disease, which is due to genetic predisposition, hypertension, impaired glucose tolerance, diabetes, obesity, dyslipidemia, atherosclerosis or cardiovascular disease. age-related diseases such as diseases; Diseases such as cancer, autoimmune diseases, infectious diseases, AIDS, chronic inflammatory diseases, arthritis, malnutrition, kidney disease, chronic obstructive pulmonary disease, emphysema, rickets, chronic lower back pain, peripheral nerve damage, central nerve damage and chemical damage chronic diseases such as; loss of motion due to causes such as fractures, trauma, etc., or prolonged bed rest; It can be caused by various causes such as aging.
이에 제한되는 것은 아니나, 상기 근육 질환은 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근경직증, 근위축성 축삭경화증, 근무력증, 악액질 (cachexia) 및 노인성 근육감소증(sarcopenia)으로 이루어진 군에서 선택되는 하나 이상의 근육질환일 수 있다. 특히 본 발명에서 상기 근육 질환은 근위축증(muscular atrophy), 노화로 인한 근감소증(sarcopenia) 또는 근이영양증(근육 퇴행 위축, muscular dystrophy)으로 이루어진 군에서 선택되는 하나 이상의 근육 질환일 수 있다.
Although not limited thereto, the muscle diseases include atony, muscular atrophy, muscular dystrophy, muscle degeneration, muscle stiffness, amyotrophic sclerosis, myasthenia, cachexia and geriatric sarcopenia. (sarcopenia) may be one or more muscle diseases selected from the group consisting of. In particular, in the present invention, the muscle disease may be at least one muscle disease selected from the group consisting of muscular atrophy, sarcopenia due to aging, or muscular dystrophy.
본 명세서에서 용어 "예방"은 본 발명에 따른 상기 약학적 조성물의 투여에 의해 근육 질환을 억제시키거나 발병을 지연시킬 수 있는 모든 행위를 의미한다. As used herein, the term "prevention" refers to all actions capable of suppressing or delaying the onset of muscle diseases by administration of the pharmaceutical composition according to the present invention.
본 명세서에서 용어 "치료"는 본 발명에 따른 상기 약학적 조성물의 투여에 의해 증세가 호전되거나 이롭게 되는 모든 행위를 말한다. As used herein, the term "treatment" refers to all activities that improve or benefit symptoms by administration of the pharmaceutical composition according to the present invention.
본 발명의 상기 약학적 조성물은 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 상기 제형화에 필요한 담체 혹은 부형제 등을 추가로 포함할 수 있다. 상기 유효 성분에 추가로 포함될 수 있는 약학적으로 허용 가능한 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 마그네슘 스테아레이트 및 광물유 등이 포함된다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. The pharmaceutical composition of the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods. and may further include carriers or excipients necessary for the formulation. Pharmaceutically acceptable carriers, excipients and diluents that may be further included in the active ingredient include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oil; and the like. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
예를 들어, 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물 또는 화합물에 적어도 하나 이상의 부형제 적어도 면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스 (sucrose) 또는 락토오스 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. For example, solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient at least cotton, starch, calcium carbonate, etc. in the extract or compound. It is prepared by mixing sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin fat, glycerogeratin and the like may be used.
본 발명의 약학적 조성물은 목적하는 방법에 따라 경구 또는 비경구 투여(정맥주사, 피하, 복강 내 또는 국소에 적용)될 수 있으며, 투여량은 환자의 상태 및 체중, 질병의 정도 및 약물 형태, 투여 경로 및 시간에 따라 다르며, 당업자에 의해 적절한 형태로 선택될 수 있다. The pharmaceutical composition of the present invention may be administered orally or parenterally (intravenously, subcutaneously, intraperitoneally or topically applied) depending on the desired method, and the dosage may be the condition and weight of the patient, the severity of the disease and the type of drug, Depending on the route and time of administration, it can be selected in an appropriate form by those skilled in the art.
본 발명의 상기 약학적 조성물은, 약학적으로 유효한 양으로 투여한다. 본 발명에서 "약학적으로 유효한 양"이란 의학적 치료에 적용 가능한 합리적인 양으로, 질병을 치료하기에 충분한 양을 의미하며, 그 기준은 환자의 질환, 중증도, 약물 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 병용되는 성분 및 기타 사항에 따라 결정될 수 있다. 본 발명의 상기 약학적 조성물은, 개별 치료제 혹은 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용을 최소화할 수 있는 수준으로 투여량을 결정할 수 있고, 이는 당업자에 의해 용이한 수준으로 결정될 수 있다. 구체적으로 상기 약학적 조성물의 투여량은 환자의 연령, 체중, 중증도, 성별 등에 따라 달라질 수 있으며, 일반적으로 체중 1kg 당 0.001 내지 150 mg, 보다 바람직하게는 0.01 내지 100mg의 양을 매일 또는 격일, 1일 1 내지 3회 투여할 수 있다. 다만, 이는 예시적인 것으로, 상기 투여량은 필요에 달리 설정할 수 있다. The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means a reasonable amount applicable to medical treatment, an amount sufficient to treat a disease, and the standard is the patient's disease, severity, drug activity, sensitivity to the drug, administration time , route of administration and excretion rate, duration of treatment, concomitant components, and other factors. The pharmaceutical composition of the present invention may be administered individually or in combination with other therapeutic agents, or may be administered sequentially or simultaneously with conventional therapeutic agents. The dosage can be determined at a level that can minimize side effects by considering all of the above factors, which can be easily determined by a person skilled in the art. Specifically, the dosage of the pharmaceutical composition may vary depending on the patient's age, weight, severity, sex, etc., and is generally 0.001 to 150 mg per 1 kg of body weight, more preferably 0.01 to 100 mg per day or every other day, 1 It can be administered 1 to 3 times a day. However, this is exemplary, and the dosage may be set differently if necessary.
또한 본 발명의 상기 조성물은 기능성 식품, 식품 보조제 또는 건강기능식품일 수 있으며, 특히 상기 "건강기능식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In addition, the composition of the present invention may be a functional food, food supplement or health functional food, and in particular, the "health functional food" uses raw materials or components having useful functionality for the human body according to Health Functional Food Act No. 6727. "Functional" refers to food that has been manufactured and processed, and "functional" means to be ingested for the purpose of obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological actions.
본 발명의 상기 식품 또는 건강기능식품은, 근육 질환의 예방 및 개선을 위한 목적으로 산제, 과립제, 정제, 캡슐제, 환제, 현탁액, 에멀젼, 시럽 등 약학적 투여 형태 또는 티백, 침출자, 음료, 캔디, 젤리, 껌 등의 건강 기능식품으로 제조 및 가공이 가능하다. The food or health functional food of the present invention, for the purpose of preventing and improving muscle diseases, is a pharmaceutical dosage form such as powder, granule, tablet, capsule, pill, suspension, emulsion, syrup, or tea bag, leachate, beverage, It can be manufactured and processed into health functional foods such as candy, jelly, and gum.
본 발명의 상기 식품 또는 건강기능식품 조성물은, 식품 첨가물로 사용될 수 있으며, 단독으로 혹은 다른 성분과 조합하여 제품화될 수 있다. 또한, 영양제, 비타민, 전해질, 풍미제, 착색제 및 증진제, 펙트산 및 이의 염, 알긴산 및 이의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등이 포함될 수 있다. 상기 성분은 단독 혹은 조합하여 사용될 수 있으며, 적절한 함량으로 조합되어 사용할 수 있다.The food or health functional food composition of the present invention can be used as a food additive, and can be commercialized alone or in combination with other ingredients. In addition, nutrients, vitamins, electrolytes, flavoring agents, colorants and enhancers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, used in carbonated beverages A carbonation agent and the like may be included. The above components may be used alone or in combination, and may be used in combination in an appropriate amount.
본 발명의 다른 실시 양태로서, 본 발명은 진세노사이드 Rg5를 포함하는 사료 또는 사료 첨가용 조성물에 대한 것이다. As another embodiment of the present invention, the present invention relates to a feed or feed additive composition containing ginsenoside Rg5.
본 발명에서, '사료'란, 동물의 생명을 유지하는데 필요한 유기 또는 무기 영양소를 공급하는 물질을 의미한다. 상기 사료는 가축 등의 동물이 필요로 하는 에너지, 단백질, 지질, 비타민, 광물질 등의 영양소를 포함하며, 곡물류, 근과류, 식품가공부산물류, 조류, 섬유질류, 유지류, 전분류, 박류, 곡물부산물류 등의 식물성 사료 또는 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질 등의 동물성 사료가 될 수 있으나, 이에 제한되는 것은 아니다. In the present invention, 'feed' means a material that supplies organic or inorganic nutrients necessary for maintaining the life of an animal. The feed includes nutrients such as energy, protein, lipid, vitamins, and minerals required by animals such as livestock, and includes grains, roots and fruits, food processing by-products, algae, fibers, oils, starches, It may be vegetable feed such as grain by-products or animal feed such as proteins, inorganic materials, oils, minerals, oils, and single cell proteins, but is not limited thereto.
본 발명에서, '사료 첨가제'란, 동물의 생산성 향상이나 건강을 증진시키기 위해 사료에 첨가되는 물질을 의미하며, 이에 제한되는 것은 아니나, 성장 촉진, 질병 예방 등을 위한 아미노산제, 비타민제, 효소제, 향미제, 규산염제, 완충제, 추출제, 올리고당 등이 더욱 포함될 수 있다. In the present invention, 'feed additive' means a substance added to feed to improve productivity or health of animals, but is not limited thereto, but is not limited thereto, such as amino acids, vitamins, enzymes, A flavoring agent, a silicate agent, a buffering agent, an extracting agent, an oligosaccharide, and the like may be further included.
상기 본 발명의 사료 또는 사료 첨가제에 포함되는 진세노사이드 Rg5의 함량은 특별히 이에 제한되지 않으나, 0.001 내지 1%(w/w)일 수 있고, 바람직하게는 0.005 내지 0.9%(w/w)일 수 있고, 가장 바람직하게는 0.01 내지 0.5%(w/w)일 수 있다.The content of ginsenoside Rg5 contained in the feed or feed additive of the present invention is not particularly limited thereto, but may be 0.001 to 1% (w/w), preferably 0.005 to 0.9% (w/w). It may be, and most preferably may be 0.01 to 0.5% (w / w).
본 발명은 진세노사이드 Rg5를 포함하는 조성물로서, 상기 조성물은 근원세포 분화 촉진, 근육량 증가, 근력 향상 및/또는 운동수행능력을 증가시키고, 근육 질환에 대한 예방, 개선 또는 치료 효과를 가질 수 있다. The present invention is a composition containing ginsenoside Rg5, which promotes differentiation of myoblasts, increases muscle mass, improves muscle strength and/or increases exercise performance, and may have preventive, ameliorative, or therapeutic effects on muscle diseases. .
도 1은 진세노사이드 Rg5를 근원세포(C2C12)에 농도별로 처리하였을 때, 세포 독성 여부를 확인한 결과이다. 1 is a result of confirming whether ginsenoside Rg5 is cytotoxic when myoblasts (C2C12) are treated by concentration.
도 2는 진세노사이드 Rg5를 농도별로 처리한 C2C12 세포에서 근원세포 분화 마커의 발현을 보여주는 웨스턴 블랏 결과이다. Figure 2 is a Western blot showing the expression of myoblast differentiation markers in C2C12 cells treated with ginsenoside Rg5 at different concentrations.
도 3 및 도 4는 C2C12에 진세노사이드 Rg5를 처리한 후, 3일 경과 후 근육 세포에서 MHC를 발현하는 세포의 증가를 확인한 결과이다. 3 and 4 show the results confirming the increase in MHC-expressing cells in muscle cells 3 days after C2C12 was treated with ginsenoside Rg5.
도 5a 및 5b는 덱사메타손을 처리하여 근육 손상을 유발한 후, 진세노사이드 Rg5를 처리한 경우, 근관 세포의 직경 및 회복 여부를 확인한 결과이다. 5a and 5b show the results of confirming the diameter and recovery of myotube cells in the case of treatment with ginsenoside Rg5 after inducing muscle damage by treatment with dexamethasone.
도 6은 덱사메타손 처리 시, 근육 세포의 단백질 분해에 대한 회복과 관련한 진세노사이드 Rg5의 효과를 확인한 것이다. 덱사메타손 처리 시, Atrogin-1의 발현이 증가하였으나, 진세노사이드 Rg5를 함께 처리한 경우, 발현이 감소되는 것을 확인하였으며(도 6a), 또한 MuRF1의 mRNA 발현량이 감소된 것을 확인하였다(도 6b).Figure 6 confirms the effect of ginsenoside Rg5 on the recovery of protein degradation in muscle cells upon treatment with dexamethasone. When treated with dexamethasone, the expression of Atrogin-1 increased, but when treated with ginsenoside Rg5, it was confirmed that the expression was reduced (Fig. 6a), and also, it was confirmed that the mRNA expression level of MuRF1 was reduced (Fig. 6b) .
이하, 본 명세서를 구체적으로 설명하기 위해 실시예를 들어 상세히 설명한다. 그러나, 본 명세서에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 명세서의 범위가 아래에서 상술하는 실시예들에 한정되는 것으로 해석되지는 않는다. 본 명세서의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 명세서를 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples will be described in detail in order to specifically describe the present specification. However, the embodiments according to the present specification may be modified in many different forms, and the scope of the present specification is not construed as being limited to the embodiments described below. The embodiments herein are provided to more completely explain the present specification to those skilled in the art.
실시예 1. 세포 분리 및 배양 Example 1. Cell Isolation and Culture
C2Cl2는 C3H종의 생 마우스에서 얻은 근원 세포주로서, 근세포 분화 연구에 널리 사용되고 있다. 상기 C2C12세포는 일반적인 세포 배양용 배지와 분화용 배지에서 각각 배양하였다. 정상적인 세포 배양용 배지(GM, growth media)로는 10 % 어린 소혈청(fetal bovine serum)이 첨가된 DMEM을 사용하였으며, 분화용 배지(DM, differentiation media)로는 2 % 말 혈청이 포함된 DMEM을 사용하였다. C2Cl2 is a myogenic cell line obtained from live mice of the C3H species, and is widely used in myocyte differentiation studies. The C2C12 cells were cultured in a general cell culture medium and a differentiation medium, respectively. DMEM supplemented with 10% fetal bovine serum was used as normal growth media (GM), and DMEM containing 2% horse serum was used as differentiation media (DM). did
실시예 2. 시료 준비 Example 2. Sample preparation
진세노사이드 Rg5 는 시판중인 원료(Ambo Institute)를 구입하여 사용하였다.Ginsenoside Rg5 was purchased and used as a commercially available raw material (Ambo Institute).
실험예 1. 근원세포 분화 촉진 효과 확인 Experimental Example 1. Confirmation of myoblast differentiation promoting effect
1-1) 진세노사이드 Rg5 처리 농도별 분화 촉진 효과 1-1) Differentiation promotion effect by concentration of ginsenoside Rg5 treatment
실시예 1의 C2Cl2 세포주를 세포 배양용 배지에 분주하여 DMEM 배지에서 24시간 동안 배양한 후, 분화 배지에 진세노사이드 Rg5 (0(DMSO), 30, 100, 300 및 1000 nΝ)를 각각 농도별로 처리하고 상기 배지는 격일로 교체하면서 3일 동안 분화를 유도하였다. After dividing the C2Cl2 cell line of Example 1 into a cell culture medium and culturing in DMEM medium for 24 hours, ginsenoside Rg5 (0(DMSO), 30, 100, 300 and 1000 nΝ) was added to the differentiation medium by concentration, respectively. treatment and differentiation was induced for 3 days while the medium was replaced every other day.
분화 후, 세포들을 현미경으로 확인하였으며, 세포들을 파쇄하여 분화 마커인 MHC(myosin heavy chain), Troponin-T 및 Myogenin 항체를 이용하여 웨스턴 블랏 분석을 수행하였다. 또한, 진세노사이드 Rg5의 세포 독성 여부를 확인하기 위하여 MTT 어세이를 실시하였다.After differentiation, the cells were observed under a microscope, and the cells were disrupted and Western blot analysis was performed using the differentiation markers MHC (myosin heavy chain), Troponin-T, and Myogenin antibodies. In addition, an MTT assay was performed to determine whether ginsenoside Rg5 was cytotoxic.
MTT 어세이 결과, 도 1에서 보듯이, 비처리군과 비교하여 진세노사이드 Rg5 의 고 농도 처리군에서 특별히 세포독성이 나타나지 않은 것을 확인하였다. 또한 도 2 및 도 3에서 보듯이, 진세노사이드 Rg5를 처리한 경우, 분화 마커인 MHC(myosin heavy chain), Troponin-T 및 미오게닌의 발현량이 진세노사이드 Rg5의 처리 농도에 의존적으로 증가된 것을 확인하였으며(도 2), 분화가 촉진된 것을 확인할 수 있었으며, MHC의 상대적 발현량이 진세노사이드 Rg5 처리 농도 의존적으로 증가된 것을 확인할 수 있었다. As a result of the MTT assay, as shown in FIG. 1, it was confirmed that cytotoxicity was not particularly observed in the high concentration treatment group of ginsenoside Rg5 compared to the untreated group. In addition, as shown in FIGS. 2 and 3, when ginsenoside Rg5 was treated, the expression levels of differentiation markers MHC (myosin heavy chain), Troponin-T, and myogenin increased depending on the treatment concentration of ginsenoside Rg5. (FIG. 2), it was confirmed that differentiation was promoted, and it was confirmed that the relative expression level of MHC was increased in a concentration-dependent manner when ginsenoside Rg5 was treated.
1-2) 진세노사이드 Rg5 처리 시간에 따른 분화 촉진 효과 1-2) Differentiation promotion effect according to ginsenoside Rg5 treatment time
300nM의 진세노사이드 Rg5가 포함된 분화유도배지를 배양 배지에 첨가한 후, 근육 세포(다핵)를 3일간 배양하였다. 이후, 근육 세포에서 MHC 발현을 확인하기 위하여 비처리군과 함께 형광 염색을 통해 확인하였다. 그 결과 도 3 및 도 4에서 보듯이, 진세노사이드 Rg5 처리 후 48시간이 경과된 후 MHC를 발현하고 있는 세포가 증가된 것을 확인하였다. 상기와 같은 결과로부터, 진세노사이드 Rg5는 근원세포가 근육세포로 분화되는 것을 촉진하는 효과를 가진다는 것을 확인할 수 있다. After adding differentiation induction medium containing 300 nM of ginsenoside Rg5 to the culture medium, muscle cells (multinucleated) were cultured for 3 days. Thereafter, in order to confirm MHC expression in muscle cells, it was confirmed through fluorescence staining together with the untreated group. As a result, as shown in FIGS. 3 and 4, it was confirmed that the number of cells expressing MHC increased after 48 hours of treatment with ginsenoside Rg5. From the above results, it can be confirmed that ginsenoside Rg5 has an effect of promoting the differentiation of myoblasts into muscle cells.
실험예 2. 근육 위축증 모델에서 근육재생 효과 Experimental Example 2. Muscle regeneration effect in muscle atrophy model
진세노사이드 Rg5가 실제 근육 질환에 대한 치료 효과를 나타내는지 여부를 확인하기 위한 실험을 수행하였다. 덱사메타손(DEX)에 의해 인위적으로 근위축을 유도하고, 이로부터 근육을 회복 또는 보호할 수 있는지 여부를 확인하기 위하여, C2C12 근원세포를 이용한 실험을 수행하였다. C2C12 근원세포를 분화배지(DM)에서 3일동안 분화 유도한 후, 여기에 100mM 덱사메타손(DEX)을 4시간 동안 전처리하였다. 이후 진세노사이드 Rg5와 DMSO 300nM을 각각 처리하고 분화 배지에서 24시간 동안 배양하였다. 그 후 면역세포화학염색을 MHC항체를 이용하여 수행하고 형광현미경으로 분석하였다.Experiments were conducted to determine whether ginsenoside Rg5 exhibits a therapeutic effect on actual muscle diseases. In order to determine whether muscle atrophy can be artificially induced by dexamethasone (DEX) and muscles can be recovered or protected therefrom, an experiment using C2C12 myoblasts was performed. After differentiation of C2C12 myoblasts was induced in differentiation medium (DM) for 3 days, they were pretreated with 100 mM dexamethasone (DEX) for 4 hours. Thereafter, ginsenoside Rg5 and DMSO were treated with 300 nM, respectively, and cultured in a differentiation medium for 24 hours. Thereafter, immunocytochemical staining was performed using an MHC antibody and analyzed by fluorescence microscopy.
그 결과, DEX를 처리한 C2C12 근관(myotube)은 대조군(DMSO 처리군) 대비 근관 직경이 얇아지고 근관이 중간중간 잘라지는 것을 확인하였다. 그러나, 진세노사이드 Rg5를 처리한 경우, DEX에 의해 얇아진 근관 직경을 대조군 (DMSO 처리군)과 동등한 수준으로 회복/개선시키는 효과를 확인하였다(도 5).As a result, it was confirmed that the diameter of the C2C12 myotube treated with DEX was thinner than that of the control group (DMSO-treated group) and the root canal was cut in the middle. However, when ginsenoside Rg5 was treated, the effect of restoring/improving the root canal diameter thinned by DEX to the same level as that of the control group (DMSO-treated group) was confirmed (FIG. 5).
또한, 근육 세포에서 단백질의 분해에 관여하는 마커로서, 근 위축증을 확인할 수 있는 Atrogin-1과 MuRF1의 발현을 확인하였다. 상기 마커들의 웨스턴 블랏 및 mRNA 발현량을 비교 분석한 결과, 진세노사이드 Rg5 처리 시 대조군 대비 Atrogin-1 단백질 발현이 감소하고 MuRF1 mRNA 발현이 유의성 있게 감소되는 것을 확인하였다. (도 6)In addition, as markers involved in protein degradation in muscle cells, the expression of Atrogin-1 and MuRF1, which can confirm muscular dystrophy, was confirmed. As a result of comparative analysis of western blot and mRNA expression levels of the markers, it was confirmed that Atrogin-1 protein expression was reduced and MuRF1 mRNA expression was significantly reduced compared to the control group when ginsenoside Rg5 was treated. (FIG. 6)
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, the present invention has been looked at with respect to its preferred embodiments. Those skilled in the art to which the present invention pertains will be able to understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent range should be construed as being included in the present invention.
본 발명의 일 양태로서 본 발명은 진세노사이드 Rg5를 유효 성분으로 포함하는 근원세포 분화용 조성물에 대한 것이다. As one aspect of the present invention, the present invention relates to a composition for myoblast differentiation comprising ginsenoside Rg5 as an active ingredient.
본 발명의 다른 양태로서 본 발명은 진세노사이드 Rg5를 유효 성분으로 포함하는 근육 재생 촉진용 조성물에 대한 것이다. As another aspect of the present invention, the present invention relates to a composition for promoting muscle regeneration comprising ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 양태로서 본 발명은 진세노사이드 Rg5를 유효 성분으로 포함하는 근육량 증가용 조성물에 대한 것이다. As another aspect of the present invention, the present invention relates to a composition for increasing muscle mass comprising ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 양태로서 본 발명은 진세노사이드 Rg5를 유효 성분으로 포함하는 근력 강화 또는 운동 수행능력 향상용 조성물에 대한 것이다. As another aspect of the present invention, the present invention relates to a composition for strengthening muscle strength or improving exercise performance containing ginsenoside Rg5 as an active ingredient.
일 측면에서 상기 조성물은 약학적 조성물, 건강기능식품 조성물, 식품 첨가제 조성물 또는 사료 조성물 중 하나 이상 선택될 수 있다. In one aspect, the composition may be one or more selected from a pharmaceutical composition, a health functional food composition, a food additive composition, or a feed composition.
본 발명의 또 다른 양태로서 본 발명은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 치료용 약학적 조성물에 대한 것이다. As another aspect of the present invention, the present invention relates to a pharmaceutical composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 양태로서 본 발명은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 개선용 건강 기능식품 조성물에 대한 것이다. As another aspect of the present invention, the present invention relates to a health functional food composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
본 발명의 또 다른 양태로서 본 발명은 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 개선용 사료 또는 사료 첨가제 조성물에 대한 것이다. As another aspect of the present invention, the present invention relates to a feed or feed additive composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
일 측면에서 상기 근육 질환은 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근경직증, 근위축성 축삭경화증, 근무력증, 악액질 (cachexia) 및 근육감소증(sarcopenia)을 포함하는 군으로부터 선택될 수 있다. In one aspect, the muscular disease includes atony, muscular atrophy, muscular dystrophy, muscle degeneration, muscle stiffness, amyotrophic sclerosis, myasthenia, cachexia and sarcopenia. It may be selected from the group containing
Claims (9)
- 진세노사이드 Rg5를 유효 성분으로 포함하는 근원세포 분화용 조성물.A composition for myoblast differentiation comprising ginsenoside Rg5 as an active ingredient.
- 진세노사이드 Rg5를 유효 성분으로 포함하는 근육 재생 촉진용 조성물.A composition for promoting muscle regeneration comprising ginsenoside Rg5 as an active ingredient.
- 진세노사이드 Rg5를 유효 성분으로 포함하는 근육량 증가용 조성물. A composition for increasing muscle mass comprising ginsenoside Rg5 as an active ingredient.
- 진세노사이드 Rg5를 유효 성분으로 포함하는 근력 강화 또는 운동 수행능력 향상용 조성물.A composition for strengthening muscle strength or improving exercise performance, comprising ginsenoside Rg5 as an active ingredient.
- 제1항 내지 제4항 중 어느 한 항에 있어서, According to any one of claims 1 to 4,상기 조성물은 약학적 조성물, 건강기능식품 조성물, 식품 첨가제 조성물 또는 사료 조성물 중 하나 이상 선택되는 것인 조성물. The composition is a pharmaceutical composition, a health functional food composition, a composition that is selected from at least one food additive composition or feed composition.
- 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 치료용 약학적 조성물. A pharmaceutical composition for preventing or treating muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 개선용 건강 기능식품 조성물.A health functional food composition for preventing or improving muscle diseases, comprising ginsenoside Rg5 as an active ingredient.
- 진세노사이드 Rg5를 유효성분으로 포함하는 근육 질환의 예방 또는 개선용 사료 또는 사료 첨가제 조성물. A feed or feed additive composition for preventing or improving muscle diseases comprising ginsenoside Rg5 as an active ingredient.
- 제6항 내지 8항 중 어느 한 항에 있어서, According to any one of claims 6 to 8,상기 근육 질환은 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근경직증, 근위축성 축삭경화증, 근무력증, 악액질 (cachexia) 및 근육감소증(sarcopenia)을 포함하는 군으로부터 선택되는 것인 조성물. The muscle disease is a group comprising atony, muscular atrophy, muscular dystrophy, muscle degeneration, muscle rigidity, amyotrophic sclerosis, myasthenia, cachexia and sarcopenia. A composition selected from
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0174369 | 2021-12-08 | ||
| KR1020210174369A KR20230086830A (en) | 2021-12-08 | 2021-12-08 | Composition for preventing or treating muscle disease comprising ginsenoside Rg5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023106645A1 true WO2023106645A1 (en) | 2023-06-15 |
Family
ID=86730651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2022/017181 WO2023106645A1 (en) | 2021-12-08 | 2022-11-03 | Composition for preventing or treating muscular diseases containing ginsenoside rg5 |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20230086830A (en) |
| WO (1) | WO2023106645A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140089502A (en) * | 2008-02-19 | 2014-07-15 | 주식회사 유니젠 | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of Panax species plant leaf extract and processed Panax species plant leaf extract |
| KR20170001037A (en) * | 2015-06-25 | 2017-01-04 | 서울대학교산학협력단 | The method for preparing panax ginseng extract with increased contents of selective dammaranes, and a pharmaceutical compositions of the same for prevention or treatment of sarcopenia-related diseases |
| KR101972949B1 (en) * | 2017-11-28 | 2019-04-26 | 심마니산삼영농조합법인 | Composition comprising mixture of active protopanaxadiol for improve exercise capacity |
| KR20210050475A (en) * | 2019-10-28 | 2021-05-07 | 한국식품연구원 | Composition for improving muscle function comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component |
-
2021
- 2021-12-08 KR KR1020210174369A patent/KR20230086830A/en not_active Application Discontinuation
-
2022
- 2022-11-03 WO PCT/KR2022/017181 patent/WO2023106645A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140089502A (en) * | 2008-02-19 | 2014-07-15 | 주식회사 유니젠 | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of Panax species plant leaf extract and processed Panax species plant leaf extract |
| KR20170001037A (en) * | 2015-06-25 | 2017-01-04 | 서울대학교산학협력단 | The method for preparing panax ginseng extract with increased contents of selective dammaranes, and a pharmaceutical compositions of the same for prevention or treatment of sarcopenia-related diseases |
| KR101972949B1 (en) * | 2017-11-28 | 2019-04-26 | 심마니산삼영농조합법인 | Composition comprising mixture of active protopanaxadiol for improve exercise capacity |
| KR20210050475A (en) * | 2019-10-28 | 2021-05-07 | 한국식품연구원 | Composition for improving muscle function comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component |
Non-Patent Citations (2)
| Title |
|---|
| KIM, Ryuni et al. Ginsenoside Rg5 upregulates p38MAPK and AKT/mTOR signaling-mediated myoblast differentiation and alleviates muscular-atrophy. 2021 International conference of the Korea Society for Molecular and Cellular Biology. 03-05 November 2021, poster U-35. * |
| LEE SOO-YEON, GO GA-YEON, VUONG TUAN ANH, KIM JEE WON, LEE SULLIM, JO AYOUNG, AN JUN MIN, KIM SU-NAM, SEO DONG-WAN, KIM JIN-SEOK, : "Black ginseng activates Akt signaling, thereby enhancing myoblast differentiation and myotube growth", JOURNAL OF GINSENG RESEARCH, GO'RYEO INSAM HAGHOE, SEOUL,, KR, vol. 42, no. 1, 1 January 2018 (2018-01-01), KR , pages 116 - 121, XP055657052, ISSN: 1226-8453, DOI: 10.1016/j.jgr.2017.08.009 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230086830A (en) | 2023-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019199094A1 (en) | Novel bifidobacterium longum or lactobacillus rhamnosus strain having effect of preventing or treating obesity, and use thereof | |
| KR101800632B1 (en) | Pharmaceutical composition, food composition or food additives for prevention, improvement or treatment of muscle loss, weakening, and atrophy comprising Enterococcus faecalis, it culture broth or heat killed Enterococcus faecalis as an active ingredient | |
| WO2018117659A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
| WO2014058142A1 (en) | Pharmaceutical composition containing aster glehni extract as active ingredientfor preventing or treating obesity or metabolic diseases | |
| WO2018090983A9 (en) | Saponin compound for improving intestinal microflora, preparation method and use thereof | |
| US20110160136A1 (en) | Polyphenols for the treatment of cartilage disorders | |
| WO2020076043A1 (en) | Gut microbiota having prophylactic or therapeutic effect on depression and use thereof | |
| WO2017014502A1 (en) | Pharmaceutical composition for preventing or treating il-6-mediated diseases comprising rosa rugosa flower extract as active ingredient | |
| WO2020149647A1 (en) | Composition for preventing, alleviating or treating neurodegenerative diseases, comprising pediococcus inopinatus | |
| WO2017191856A1 (en) | Antidiabetic effect of gypenoside 75 | |
| WO2016208910A1 (en) | Composition containing osmotin protein or osmotin peptide as active ingredient for prevention or treatment of liver function and kidney function disorders | |
| WO2020226467A1 (en) | Enterococcus lactis wikim0107 strain having effects of regulating immune functions and alleviating inflammatory bowel disease and use thereof | |
| WO2020226468A1 (en) | Pediococcus inopinatus ｗikim0108 strain having effect of regulating immune function and alleviating inflammatory bowel disease, and use thereof | |
| WO2023106645A1 (en) | Composition for preventing or treating muscular diseases containing ginsenoside rg5 | |
| CN111388490A (en) | Ginsenoside composition with function of preventing and treating alcoholic fatty liver | |
| WO2010095808A2 (en) | Production method for astragalus membranaceus extract employing enzymolysis, and a composition for preventing or alleviating diabetes or obesity containing an active ingredient comprising an astragalus membranaceus extract produced by means of the production method | |
| EP4342474A1 (en) | Composition comprising inotodiol for prevention or treatment of muscular disease | |
| JP2022110113A (en) | Pharmaceutical composition, food composition and food additive for preventing, alleviating or treating muscle loss, weakness and atrophy, containing, as active ingredient, enterococcus faecalis, culture liquid thereof or dead cells thereof | |
| WO2012074184A1 (en) | Pharmaceutical composition for preventing or treating obesity comprising sphingosine-1-phosphate or a pharmaceutically acceptable salt thereof as an active ingredient | |
| WO2019051789A1 (en) | Anaerofustis stercorihominis and applications thereof | |
| WO2022173273A1 (en) | Composition comprising aronia extract for preventing or treating muscular disease | |
| WO2024053761A1 (en) | Composition for promoting myoblast proliferation and differentiation containing aldose reductase inhibitor | |
| WO2024038934A1 (en) | Composition containing osmotin protein as active ingredient for prevention, alleviation, or treatment of parkinson's disease | |
| WO2017142255A1 (en) | Composition containing medicinal herb extract as active ingredient for preventing, alleviating, or treating stress or depression | |
| WO2022244929A1 (en) | Composition comprising inotodiol for prevention or treatment of muscular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22904479 Country of ref document: EP Kind code of ref document: A1 |